Dengue virus: Viral targets and antiviral drugs;Le virus de la dengue: Cibles virales et antiviraux

Virologie

Volumn 11, Issue 2, 2007, Pages 121-133

  Masse N ^a   Selisko, B ^a   Malet, H ^a   Peyrane, F ^a   Debarnot, C ^a   Decroly, E ^a   Benarroch, D ^a   Egloff, M P ^a   Guillemot, J C ^a   Alvarez, K ^a   Canard, B ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Antiviral chemotherapy; Dengue; Screening; Viral replication

Indexed keywords

DENGUE VACCINE; METHYLTRANSFERASE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; PROTEINASE; RNA POLYMERASE; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

CARBOXY TERMINAL SEQUENCE; DENGUE; DRUG DESIGN; DRUG SYNTHESIS; ENZYME ACTIVITY; NONHUMAN; PROTEIN DOMAIN; PROTEIN STRUCTURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; VIRUS REPLICATION;

DENGUE VIRUS;

EID: 34250307704     PISSN: 12678694     EISSN: None     Source Type: Journal    
DOI: 10.1684/vir.2007.0047     Document Type: Review

References (86)

1. http ://www.who.int/csr/resources/publications/dengue/Denguepublication/ en/print.html.
2. Burke D, Monath TP. Flaviviruses. In : Knipe DH, ed. Flaviviruses. Lippincott Williams & Wilkins, 2001.
3. http ://martinique.sante.gouv.fr/documents/accueil/cire/dengue/psage/ psage_dengue.pdf.
4. http ://www.sante.gouv.fr/adm/dagpb/bo/2006/06-07/a0070026.htm.
5. Kouri G, Guzman MG, Valdes L, et al. Reemergence of dengue in Cuba : a 1997 epidemic in Santiago de Cuba. Emerg Infect Dis 1998 ; 4 : 89-92.
6. Chaturvedi UC, Shrivastava R, Nagar R. Dengue vaccines : problems and prospects. Indian J Med Res 2005 ; 121 : 639-52.
7. Kurane I, Ennis FA. Immunopathogenesis of dengue virus infections. In : Gubler DJ, Kuno G, eds. Immunopathogenesis of dengue virus infections. CAB International, 1997.
8. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 2006 ; 80 : 10208-17.
9. Teles FR, Prazeres DM, Lima-Filho JL. Trends in dengue diagnosis. Rev Med Virol 2005 ; 15 : 287-302.
10. Gibbons RV, Vaughn DW. Dengue : an escalating problem. BMJ 2002 ; 324 : 1563-6.
11. Dussart P, Labeau B, Lagafhu G, et al. Evaluation of an enzyme immunoassay for detection of dengue virus NS1 antigen in human serum. Clin Vaccine Immunol 2006 ; 13 : 1185-9.
12. Kumarasamy V, Wahab AH, Chua SK, et al. Evaluation of a commercial dengue NS1 antigen-capture Elisa for laboratory diagnosis of acute dengue virus infection. J Virol Methods 2007 ; 140 : 75-9.
13. Wang WK, Chao DY, Kao CL, et al. High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever : implications for pathogenesis. Virology 2003 ; 305 : 330-8.
14. Libraty DH, Young PR, Pickering D, et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis 2002 ; 186 : 1165-8.
15. Dutartre H, Bussetta C, Boretto J, Canard B. General catalytic deficiency of S282t Hcv Rna polymerase and mutually exclusive resistance towards 2′-modified nucleotide analogues. Antimicrob Agents Chemother, 2006.
16. Selmi B, Deval J, Boretto J, Canard B. Nucleotide analogue binding, catalysis and primer unblocking in the mechanisms of HIV-1 reverse transcriptase-mediated resistance to nucleoside analogues. Antivir Ther 2003 ; 8 : 143-54.
17. De Clercq E. Recent highlights in the development of new antiviral drugs. Curr Opin Microbiol 2005 ; 8 : 552-60.
18. http ://www.hcvadvocate.org/hepatitis/hepC/HCVDrugs_2006.pdf.
19. http ://www.clinicaltrials.gov/(l'identifiant de l'essai est : NCT00391313).
20. Cassells AC. Chemical control of virus diseases of plants. Prog Med Chem 1983 ; 20 : 119-55.
21. Vlietinck AJ, Vanden Berghe DA. Can ethnopharmacology contribute to the development of antiviral drugs? J Ethnopharmacol 1991 ; 32 : 141-53.
22. Cos P, Maes L, Vanden Berghe D, Hermans N, Pieters L, Vlietinck A. Plant substances as anti-HIV agents selected according to their putative mechanism of action. J Nat Prod 2004 ; 67 : 284-93.
23. Khan MT, Ather A, Thompson KD, Gambari R. Extracts and molecules from medicinal plants against herpes simplex viruses. Antiviral Res 2005 ; 67 : 107-19.
24. Clyde K, Kyle JL, Harris E. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol 2006 ; 80 : 11418-31.
25. Falgout B, Pethel M, Zhang YM, Lai CJ. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J Virol 1991 ; 65 : 2467-75.
26. Ackermann M, Padmanabhan R. De novo synthesis of RNA by the dengue virus RNA-dependent RNA polymerase exhibits temperature dependence at the initiation but not elongation phase. J Biol Chem 2001 ; 276 : 39926-37.
27. Kao CC, Singh P, Ecker DJ. De novo initiation of viral RNA-dependent RNA synthesis. Virology 2001 ; 287 : 251-60.
28. Li H, Clum S, You S, Ebner KE, Padmanabhan R. The serine protease and RNA-stimulated nucleoside triphosphatase and RNA helicase functional domains of dengue virus type 2 NS3 converge within a region of 20 amino acids. J Virol 1999 ; 73 : 3108-16.
29. Bartelma G, Padmanabhan R. Expression, purification, and characterization of the RNA 5′-triphosphatase activity of dengue virus type 2 nonstructural protein 3. Virology 2002 ; 299 : 122-32.
30. Egloff MP, Benarroch D, Selisko B, Romette JL, Canard B. An RNA cap (nucleoside-2′-O-)-methyltransferase in the flavivirus RNA polymerase NS5 : crystal structure and functional characterization. EMBO J 2002 ; 21 : 2757-68.
31. Ray D, Shah A, Tilgner M, et al. West Nile virus 5′-cap structure is formed by sequential guanine N-7 and ribose 2′-O methylations by nonstructural protein 5. J Virol 2006 ; 80 : 8362-70.
32. http ://www.nitd.novartis.com/downloads/dengue_digest_vol_2_no_1 _april. pdf.
33. Allison SL, Schalich J, Stiasny K, Mandl CW, Heinz FX. Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol 2001 ; 75 : 4268-75.
34. Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 2001 ; 75 : 7769-73.
35. Baldwin CE, Sanders RW, Berkhout B. Inhibiting HIV-1 entry with fusion inhibitors. Curr Med Chem 2003 ; 10 : 1633-42.
36. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41 -mediated virus entry. Nat Med 1998 ; 4 : 1302-7.
37. Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature 2004 ; 427 : 313-9.
38. Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 2003 ; 100 : 6986-91.
39. http ://www.aidsmeds.com/PIs.htm.
40. Murthy HM, Clum S, Padmanabhan R. Dengue virus NS3 serine protease. Crystal structure and insights into interaction of the active site with substrates by molecular modeling and structural analysis of mutational effects. J Biol Chem 1999 ; 274 : 5573-80.
41. Arias CF, Preugschat F, Strauss JH. Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain. Virology 1993 ; 193 : 888-99.
42. Clum S, Ebner KE, Padmanabhan R. Cotranslational membrane insertion of the serine proteinase precursor NS2B-NS3 (Pro) of dengue virus type 2 is required for efficient in vitro processing and is mediated through the hydrophobic regions of NS2B. J Biol Chem 1997 ; 272 : 30715-23.
43. Leung D, Schroder K, White H, et al. Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J Biol Chem 2001 ; 276 : 45762-71.
44. Yusof R, Clum S, Wetzel M, Murthy HM, Padmanabhan R. Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J Biol Chem 2000 ; 275 : 9963-9.
45. Chanprapaph S, Saparpakorn P, Sangma C, et al. Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites. Biochem Biophys Res Commun 2005 ; 330 : 1237-46.
46. Yin Z, Patel SJ, Wang WL, et al. Peptide inhibitors of dengue virus NS3 protease. Part 2 : SAR study of tetrapeptide aldehyde inhibitors. Bioorg Med Chem Lett 2006 ; 16 : 40-3.
47. Yin Z, Patel SJ, Wang WL, et al. Peptide inhibitors of Dengue virus NS3 protease. Part 1 : Warhead. Bioorg Med Chem Lett 2006 ; 16 : 36-9.
48. Murthy HM, Judge K, DeLucas L, Padmanabhan R. Crystal structure of Dengue virus NS3 protease in complex with a Bowman-Birk inhibitor : implications for flaviviral polyprotein processing and drug design. J Mol Biol 2000 ; 301 : 759-67.
49. Ganesh VK, Muller N, Judge K, Luan CH, Padmanabhan R, Murthy KH. Identification and characterization of nonsubstrate based inhibitors of the essential dengue and West Nile virus proteases. Bioorg Med Chem 2005 ; 13 : 257-64.
50. Li J, Lim SP, Beer D, et al. Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J Biol Chem 2005 ; 280 : 28766-74.
51. Kiat TS, Pippen R, Yusof R, Ibrahim H, Khalid N, Rahman NA. Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease. Bioorg Med Chem Lett 2006 ; 16 : 3337-40.
52. Erbel P, Schiering N, D' Arcy A, et al. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol 2006 ; 13 : 372-3.
53. Crute JJ, Grygon CA, Hargrave KD, et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med 2002 ; 8 : 386-91.
54. Kleymann G. Agents and strategies in development for improved management of herpes simplex virus infection and disease. Expert Opin Investig Drugs 2005 ; 14 : 135-61.
55. Benarroch D, Selisko B, Locatelli GA, Maga G, Romette JL, Canard B. The RNA helicase, nucleotide 5′-triphosphatase, and RNA 5′- triphosphatase activities of Dengue virus protein NS3 are Mg2 +-dependent and require a functional Walker B motif in the helicase catalytic core. Virology 2004 ; 328 : 208-18.
56. Caruthers JM, McKay DB. Helicase structure and mechanism. Curr Opin Struct Biol 2002 ; 12 : 123-33.
57. Xu T, Sampath A, Chao A, et al. Structure of the Dengue virus helicase/nucleoside triphosphatase catalytic domain at a resolution of 2.4 A. J Virol 2005 ; 79 : 10278-88.
58. Sampath A, Xu T, Chao A, Luo D, Lescar J, Vasudevan SG. Structure-based mutational analysis of the NS3 helicase from dengue virus. J Virol 2006 ; 80 : 6686-90.
59. Zhang N, Chen HM, Koch V, et al. Ring-expanded ("fat") nucleoside and nucleotide analogues exhibit potent in vitro activity against flaviviridae NTPases/helicases, including those of the West Nile virus, hepatitis C virus, and Japanese encephalitis virus. J Med Chem 2003 ; 46 : 4149-64.
60. http ://www.nitd.novartis.com/includes/teasers/teaser_attaches/ dengue _diguest/Dengue%20Digest%20Vol1%20No%202.pdf.
61. Parkes KE, Ermert P, Fassler J, et al. Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors. J Med Chem 2003 ; 46 : 1153-64.
62. Singh SB, Tomassini JE. Synthesis of natural flutimide and analogous fully substituted pyrazine-2,6-diones, endonuclease inhibitors of influenza virus. J Org Chem 2001 ; 66 : 5504-16.
63. Koonin EV. Computer-assisted identification of a putative methyltransferase domain in NS5 protein of flaviviruses and lambda 2 protein of reovirus. J Gen Virol 1993 ; 74 : 733-40.
64. Benarroch D, Egloff MP, Mulard L, Guerreiro C, Romette JL, Canard B. A structural basis for the inhibition of the NS5 dengue virus mRNA 2′-O-methyltransferase domain by ribavirin 5′-triphosphate. J Biol Chem 2004 ; 279 : 35638-43.
65. Koonin EV. The phylogeny of RNA-dependent RNA polymerases of positive-strand RNA viruses. J Gen Virol 1991 ; 72 : 2197-206.
66. Nomaguchi M, Ackermann M, Yon C, You S, Padmanabhan R. De novo synthesis of negative-strand RNA by Dengue virus RNA-dependent RNA polymerase in vitro : nucleotide, primer, and template parameters. J Virol 2003 ; 77 : 8831-42.
67. Selisko B, Dutartre H, Guillemot JC, et al. Comparative mechanistic studies of de novo RNA synthesis by flavivirus RNA-dependent RNA polymerases. Virology 2006 ; 351 : 145-58.
68. Malet H, Egloff M, Selisko B, et al. Crystal structure of the RNA polymerase domain of West Nile Virus NS5. sous presse.
69. Ago H, Adachi T, Yoshida A, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure 1999 ; 7 : 1417-26.
70. Bressanelli S, Tomei L, Rey FA, De Francesco R. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J Virol 2002 ; 76 : 3482-92.
71. Choi KH, Groarke JM, Young DC, et al. The structure of the RNA-dependent RNA polymerase from bovine viral diarrhea virus establishes the role of GTP in de novo initiation. Proc Natl Acad Sci USA 2004 ; 101 : 4425-30.
72. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 1999 ; 6 : 937-43.
73. Filomatori CV, Lodeiro MF, Alvarez DE, Samsa MM, Pietrasanta L, Gamarnik AV. A 5′ RNA element promotes dengue virus RNA synthesis on a circular genome. Genes Dev 2006 ; 20 : 2238-49.
74. Koch U, Narjes F. Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase. Infect Disord Drug Targets 2006 ; 6 : 31-41.
75. Mackenzie JM, Khromykh AA, Jones MK, Westaway EG. Subcellular localization and some biochemical properties of the flavivirus Kunjin nonstructural proteins NS2A and NS4A. Virology 1998 ; 245 : 203-15.
76. Westaway EG, Mackenzie JM, Kenney MT, Jones MK, Khromykh AA. Ultrastructure of Kunjin virus-infected cells : colocalization of NS1 and NS3 with double-stranded RNA, and of NS2B with NS3, in virus-induced membrane structures. J Virol 1997 ; 71 : 6650-61.
77. Vasudevan SG, Johansson M, Brooks AJ, Llewellyn LE, Jans DA. Characterisation of inter- and intra-molecular interactions of the dengue virus RNA dependent RNA polymerase as potential drug targets. Farmaco 2001 ; 56 : 33-6.
78. Kapoor M, Zhang L, Ramachandra M, Kusukawa J, Ebner KE, Padmanabhan R. Association between NS3 and NS5 proteins of dengue virus type 2 in the putative RNA replicase is linked to differential phosphorylation of NS5. J Biol Chem 1995 ; 270 : 19100-6.
79. Yon C, Teramoto T, Mueller N, et al. Modulation of the nucleoside triphosphatase/RNA helicase and 5′-RNA triphosphatase activities of Dengue virus type 2 nonstructural protein 3 (NS3) by interaction with NS5, the RNA-dependent RNA polymerase. J Biol Chem 2005 ; 280 : 27412-9.
80. Umareddy I, Chao A, Sampath A, Gu F, Vasudevan SG. Dengue virus NS4B interacts with NS3 and dissociates it from single-stranded RNA. J Gen Virol 2006 ; 87 : 2605-14.
81. Puig-Basagoiti F, Deas TS, Ren P, Tilgner M, Ferguson DM, Shi PY. High-throughput assays using a luciferase-expressing replicon, virus-like particles, and full-length virus for West Nile virus drug discovery. Antimicrob Agents Chemother 2005 ; 49 : 4980-8.
82. Goodell JR, Puig-Basagoiti F, Forshey BM, Shi PY, Ferguson DM. Identification of compounds with anti-West Nile Virus activity. J Med Chem 2006 ; 49 : 2127-37.
83. Gu B, Ouzunov S, Wang L, et al. Discovery of small molecule inhibitors of West Nile virus using a high-throughput sub-genomic replicon screen. Antiviral Res 2006 ; 70 : 39-50.
84. Laille M, Gerald F, Debitus C. In vitro antiviral activity on dengue virus of marine natural products. Cell Mol Life Sci 1998 ; 54 : 167-70.
85. Ojwang JO, Ali S, Smee DF, Morrey JD, Shimasaki CD, Sidwell RW. Broad-spectrum inhibitor of viruses in the Flaviviridae family. Antiviral Res 2005 ; 68 : 49-55.
86. Puig-Basagoiti F, Tilgner M, Forshey BM, et al. Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob Agents Chemother 2006 ; 50 : 1320-9.